000			03398nam a22005535i 4500
999			_c200457104 _d75316
003			DE-He213
005			20231109085746.0
007			cr nn 008mamaa
008			221118s2022 sz | s |||| 0|eng d
020			_a9783031063572
024	7		_a10.1007/978-3-031-06357-2 _2doi
040			_aTR-AnTOB _beng _erda _cTR-AnTOB
060			_aQZ 275
072		7	_aMJCL _2bicssc
072		7	_aMED062000 _2bisacsh
072		7	_aMJCL _2thema
096			_aQZ275EBK
245	1	0	_aPediatric Cancer Therapeutics Development _h[electronic resource] / _cedited by Jorge DiMartino, Gregory H. Reaman, Franklin O. Smith.
250			_a1st ed. 2022.
264		1	_aCham : _bSpringer International Publishing : _bImprint: Springer, _c2022.
300			_a1 online resource
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
347			_atext file _bPDF _2rda
490	1		_aPediatric Oncology, _x2191-0812
505	0		_aHistory of Drug Development -- Target Identification/Validation and Drug Discovery -- Non-Clinical Toxicology -- Study Design and Biostatistics -- Personalized Medicine and Its Impact on Study Design -- Gene and Cellular Therapy -- The Pharma/Biotech Model for Drug Development -- Clinical Research Organizations -- Role of Patients and Advocates in Cancer Therapeutics -- Development -- International Regulatory Agencies -- Ethical Considerations in Cancer Therapeutics Development -- Future Directions: Jorge DiMartino. .
520			_aThis book provides a comprehensive overview of the scientific, medical, regulatory, and economic considerations associated with the discovery, development, and delivery of novel therapeutics for children with cancer. Co-authored by a diverse team from academic, government, and industry backgrounds, the book describes the steps in the process from the identification of a promising therapeutic target to the evaluation of drug candidates in the various phases of clinical testing and regulatory review. Throughout, special emphasis is placed on the unique biology of pediatric malignancies and the medical and social needs of children and their families. In providing a firm grounding in the drug development process, the book will be of value to all with an interest in how medicines currently used to treat pediatric cancer were made available. This includes trainees as well as established practitioners and others participating in translational and clinical research in the academic setting.
650		0	_aOncology.
650		0	_aPediatrics.
650	1	4	_aOncology.
650	2	4	_aPediatrics.
653		0	_aNeoplasms
653		0	_aChild
653		0	_aInfant
653		0	_aNeoplasms -- therapy
700	1		_aDiMartino, Jorge. _eeditor. _4edt _4http://id.loc.gov/vocabulary/relators/edt
700	1		_aReaman, Gregory H. _eeditor. _4edt _4http://id.loc.gov/vocabulary/relators/edt
700	1		_aSmith, Franklin O. _eeditor. _4edt _4http://id.loc.gov/vocabulary/relators/edt
710	2		_aSpringerLink (Online service)
830		0	_aPediatric Oncology, _x2191-0812
856	4	0	_uhttps://doi.org/10.1007/978-3-031-06357-2 _3Springer eBooks _zOnline access link to the resource
942			_2NLM _cEBK
041			_aeng